Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders. With its unique understanding of the CNS market built over 35 years, Neuraxpharm develops and commercializes value-added medicines and consumer healthcare products for chronic patients suffering from neurological and psychiatric disorders including Epilepsy, Parkinson’s, Alzheimer’s, Depression and Psychosis. With one of the broadest and most diversified product portfolios in the market, its strong medical reputation and CNS expertise, the company enjoys leading positions in its core markets Germany and Spain, with a #1 position across Europe in many of its more than 115 CNS molecules. Present with its products in more than 50 countries, Neuraxpharm also manufactures pharmaceutical products and active pharmaceutical ingredients in its own manufacturing sites in Spain.
For more information visit www.neuraxpharm.com
Employees at entry
Country presence at entry
Permira funds to acquire leading European CNS specialty pharmaceutical company Neuraxp...
News | 22nd September 2020Find out more